Time to metastasis as a prognostic factor in metastatic
urothelial carcinoma: results from the ARON-2 study

J 2026

Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study

PICHLER, Renate; Gerald KLINGLMAIR; Kirstin BINZ; Enrique GRANDE; Alina PIRSHTUK et al.

Základní údaje

Originální název

Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study

Autoři

Vydání

CLINICAL & EXPERIMENTAL METASTASIS, DORDRECHT, SPRINGER, 2026, 0262-0898

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.200 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Chemotherapy; Enfortumab vedotin; Immunotherapy; Time to metastasis; NCT05290038; Pembrolizumab; Urothelial Carcinoma

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 3. 2026 11:51, Mgr. Tereza Miškechová

Anotace

V originále

Metastatic urothelial carcinoma (mUC) may present with metastases at the time of initial diagnosis (synchronous) or develop them during follow-up (metachronous). The impact of the timing of metastasis on the outcome of mUC remains unclear. We aimed to evaluate overall survival (OS) stratified by time to metastasis (TTM) in patients receiving systemic therapy in different lines. Retrospective real-world data from the ARON-2 study were analyzed to compare patient outcomes according to TTM. Cohort 1 included 735 patients receiving first-line platinum-based chemotherapy, Cohort 2 included 1164 patients receiving second-line pembrolizumab, Cohort 3 included 588 patients receiving third-line enfortumab vedotin. TTM (synchronous vs. < 6 months, and >= 6 months) significantly influenced overall survival (OS) in Cohort 1 (19.2 vs. 22.3 vs. 27.4 months, p = 0.004) and Cohort 2 (14.6 vs. 15.4 vs. 21.2 months, p = 0.015), but not in Cohort 3. In the multivariable Cox analysis, TTM remained an independent prognostic parameter of poor OS in Cohort 1 (hazard ratio [HR]: 1.14, 95% confidence interval [CI] 1.02-1.27; p = 0.016) and Cohort 2 (HR: 1.12, 95% CI 1.02-1.22; p = 0.014). Our findings suggest that the TTM in mUC significantly influences OS in patients receiving first-line platinum-based chemotherapy and second-line pembrolizumab. The prognostic role of TTM should be considered in the future clinical trial designs.

Citovat

PICHLER, Renate; Gerald KLINGLMAIR; Kirstin BINZ; Enrique GRANDE; Alina PIRSHTUK; Hideki TAKESHITA; Yuksel URUN; Javier MOLINA-CERRILLO; Zin W MYINT; De Liano Alfonso GOMEZ; Augusto MOTA; Alessia SALFI; Wataru FUKUOKAYA; Enrico SAMMARCO; Angel MARTIN; Jakub KUCHARZ; Deniz TURAL; Ondrej FIALA; Alejo RODRIGUEZ-VIDA; Franco MORELLI; Alexandr POPRACH; Mobin SAFI; Alvaro PINTO; Francesco MASSARI; Sebastiano BUTI; Shilpa GUPTA; Fernando Sabino Marques MONTEIRO; Andrey SOARES; Nicola BATTELLI; Ravindran KANESVARAN a Matteo SANTONI. Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study. CLINICAL & EXPERIMENTAL METASTASIS. DORDRECHT: SPRINGER, 2026, roč. 43, č. 1, s. 1-14. ISSN 0262-0898. Dostupné z: https://doi.org/10.1007/s10585-025-10382-x.

@article{2557778,
   author = {Pichler, Renate and Klinglmair, Gerald and Binz, Kirstin and Grande, Enrique and Pirshtuk, Alina and Takeshita, Hideki and Urun, Yuksel and MolinaandCerrillo, Javier and Myint, Zin W and Gomez, De Liano Alfonso and Mota, Augusto and Salfi, Alessia and Fukuokaya, Wataru and Sammarco, Enrico and Martin, Angel and Kucharz, Jakub and Tural, Deniz and Fiala, Ondrej and RodriguezandVida, Alejo and Morelli, Franco and Poprach, Alexandr and Safi, Mobin and Pinto, Alvaro and Massari, Francesco and Buti, Sebastiano and Gupta, Shilpa and Monteiro, Fernando Sabino Marques and Soares, Andrey and Battelli, Nicola and Kanesvaran, Ravindran and Santoni, Matteo},
   article_location = {DORDRECHT},
   article_number = {1},
   doi = {https://doi.org/10.1007/s10585-025-10382-x},
   keywords = {Chemotherapy; Enfortumab vedotin; Immunotherapy; Time to metastasis; NCT05290038; Pembrolizumab; Urothelial Carcinoma},
   language = {eng},
   issn = {0262-0898},
   journal = {CLINICAL & EXPERIMENTAL METASTASIS},
   title = {Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study},
   url = {https://link.springer.com/article/10.1007/s10585-025-10382-x},
   volume = {43},
   year = {2026}
}

TY  - JOUR
ID  - 2557778
AU  - Pichler, Renate - Klinglmair, Gerald - Binz, Kirstin - Grande, Enrique - Pirshtuk, Alina - Takeshita, Hideki - Urun, Yuksel - Molina-Cerrillo, Javier - Myint, Zin W - Gomez, De Liano Alfonso - Mota, Augusto - Salfi, Alessia - Fukuokaya, Wataru - Sammarco, Enrico - Martin, Angel - Kucharz, Jakub - Tural, Deniz - Fiala, Ondrej - Rodriguez-Vida, Alejo - Morelli, Franco - Poprach, Alexandr - Safi, Mobin - Pinto, Alvaro - Massari, Francesco - Buti, Sebastiano - Gupta, Shilpa - Monteiro, Fernando Sabino Marques - Soares, Andrey - Battelli, Nicola - Kanesvaran, Ravindran - Santoni, Matteo
PY  - 2026
TI  - Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study
JF  - CLINICAL & EXPERIMENTAL METASTASIS
VL  - 43
IS  - 1
SP  - 1-14
EP  - 1-14
PB  - SPRINGER
SN  - 02620898
KW  - Chemotherapy
KW  - Enfortumab vedotin
KW  - Immunotherapy
KW  - Time to metastasis
KW  - NCT05290038
KW  - Pembrolizumab
KW  - Urothelial Carcinoma
UR  - https://link.springer.com/article/10.1007/s10585-025-10382-x
N2  - Metastatic urothelial carcinoma (mUC) may present with metastases at the time of initial diagnosis (synchronous) or develop them during follow-up (metachronous). The impact of the timing of metastasis on the outcome of mUC remains unclear. We aimed to evaluate overall survival (OS) stratified by time to metastasis (TTM) in patients receiving systemic therapy in different lines. Retrospective real-world data from the ARON-2 study were analyzed to compare patient outcomes according to TTM. Cohort 1 included 735 patients receiving first-line platinum-based chemotherapy, Cohort 2 included 1164 patients receiving second-line pembrolizumab, Cohort 3 included 588 patients receiving third-line enfortumab vedotin. TTM (synchronous vs. < 6 months, and >= 6 months) significantly influenced overall survival (OS) in Cohort 1 (19.2 vs. 22.3 vs. 27.4 months, p = 0.004) and Cohort 2 (14.6 vs. 15.4 vs. 21.2 months, p = 0.015), but not in Cohort 3. In the multivariable Cox analysis, TTM remained an independent prognostic parameter of poor OS in Cohort 1 (hazard ratio [HR]: 1.14, 95% confidence interval [CI] 1.02-1.27; p = 0.016) and Cohort 2 (HR: 1.12, 95% CI 1.02-1.22; p = 0.014). Our findings suggest that the TTM in mUC significantly influences OS in patients receiving first-line platinum-based chemotherapy and second-line pembrolizumab. The prognostic role of TTM should be considered in the future clinical trial designs.
ER  -

PICHLER, Renate; Gerald KLINGLMAIR; Kirstin BINZ; Enrique GRANDE; Alina PIRSHTUK; Hideki TAKESHITA; Yuksel URUN; Javier MOLINA-CERRILLO; Zin W MYINT; De Liano Alfonso GOMEZ; Augusto MOTA; Alessia SALFI; Wataru FUKUOKAYA; Enrico SAMMARCO; Angel MARTIN; Jakub KUCHARZ; Deniz TURAL; Ondrej FIALA; Alejo RODRIGUEZ-VIDA; Franco MORELLI; Alexandr POPRACH; Mobin SAFI; Alvaro PINTO; Francesco MASSARI; Sebastiano BUTI; Shilpa GUPTA; Fernando Sabino Marques MONTEIRO; Andrey SOARES; Nicola BATTELLI; Ravindran KANESVARAN a Matteo SANTONI. Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study. \textit{CLINICAL \&{} EXPERIMENTAL METASTASIS}. DORDRECHT: SPRINGER, 2026, roč.~43, č.~1, s.~1-14. ISSN~0262-0898. Dostupné z: https://doi.org/10.1007/s10585-025-10382-x.

Přehled o publikaci